biophytis
NEW THERAPEUTICS FOR AGING DISEASES

Press Release

Biophytis clinical stage drug-candidate Sarconeos demonstrates efficacy in preclinical models of Duchenne muscular dystrophy

- Biophytis announces abstract accepted at World Muscle Society international congress (3-7 October 2017, St Malo, France)
- Duchenne muscular dystrophy is a new Orphan indication for Sarconeos

Paris (France), September 8, 2017 – BIOPHYTIS (Euronext Growth Paris: ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, today announced an abstract entitled "Sarconeos demonstrates sharp functional improvement and anti-fibrotic properties in an animal model of Duchenne muscular dystrophy" has been selected for presentation at the World Muscle Society international congress being held on 3-7 October 2017 in St Malo, France.

Stanislas Veillet, PDG de BIOPHYTIS, said: *"The abstract highlights exciting data demonstrating Sarconeos' potential ability to improve muscle function not only in sarcopenia but also in other neuro-muscular diseases, such as Duchenne. Duchenne muscular dystrophy is a debilitating progressive disease with few treatment options for patients. Sarconeos' oral delivery and safety profile could offer a promising treatment alone or combined with gene therapies when they become available. We are now designing the possible clinical roadmap for this new Orphan indication, which offers a clear regulatory path and accelerated timelines to market."*

Duchenne muscular dystrophy (DMD), is a X-linked inherited muscular disease, characterized by progressive muscle weakness and cardiomyopathy, leading to premature death. Muscles undergo repeated cycles of necrosis/regeneration and are replaced by connective and adipose tissues. Glucocorticoids and supportive therapy are the current standard of care leaving many patients with an unmet medical need.

In the study, mdx mice were treated daily with either Sarconeos for 8 weeks. Mdx mice are a gold standard animal model of Duchenne muscular dystrophy. At completion of the study, mice treated with Sarconeos showed statistically significant improvements in running distances (2.4-fold) when compared to untreated mdx mice. Additionally, the treated mice showed improvements in maximal muscle force of 15% when treated with Sarconeos. Gene expression markers in the heart for fibrosis (CTGF) and hypertrophy (my7, BMP4) were reduced in treated mice, and histopathological analysis revealed a clear decrease of muscle lesion profile, as well as a decrease in fibrosis in the treated mdx animals.

These results demonstrate the efficacy of Sarconeos in the improvement of dystrophic muscle functionality and in the prevention of fibrosis appearance and potentially open a new therapeutic option for patients with DMD.

****

About SARCONEOS

Sarconeos is a first-in-class drug candidate based on the activation of the MAS receptor (major player of the renin-angiotensin system) restoring muscular anabolism, inhibiting myostatin, and that had demonstrated meaningful activity in animal models of muscular dystrophies. Sarconeos is developed in the treatment of sarcopenia, an age-related degeneration of skeletal muscle, leading to loss of mobility in elderly people. This condition, for which no medical treatment currently exists, was first described in 1993 and has entered the International Classification of Diseases (M62.84) in 2016. It affects more than 50 million people worldwide.

About BIOPHYTIS:

Biophytis SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical needs. Specifically, the company is advancing two lead products into mid-stage clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD).
The business model of BIOPHYTIS is to ensure the conduct of the project until clinical activity in the patient is proven, then to license the technologies in order to continue the development in partnership with a pharmaceutical laboratory.
The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute.

BIOPHYTIS is listed on the Euronext Growth market of Euronext Paris (ALBPS; ISIN: FR0012816825).

For more information: http://www.biophytis.com

Follow us on Twitter @biophytis

BIOPHYTIS is eligible for the SMEs scheme

Disclaimer

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Listing Prospectus upon the admission of Company’s shares for trading on the regulated market Euronext Growth of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf- france.org) or on BIOPHYTIS’ website (www.biophytis.com).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could

differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company's prospectus. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall prevail.

BIOPHYTIS
Stanislas VEILLET
CEO
contact@biophytis.com
Tel: +33 (0) 1 41 83 66 00

Citigate Dewe Rogerson
Presse internationale & Investisseurs
Laurence BAULT/Antoine DENRY
Laurence.bault@citigate.fr/antoine.denry@citigate.fr
Tel: +33 (0)1 53 32 84 78
Mob: +33(0)6 64 12 53 61

LifeSci Advisors
Chris MAGGOS
Managing Director, Europe
chris@lifesciadvisors.com
Tel: +41 79 367 6254